Search ↗

Comparison

Argireline vs Pentapeptide-18

Both are cosmetic & topical, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Argireline is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

Argireline Pentapeptide-18
Class Cosmetic & topical Cosmetic & topical
Evidence Clinical trials Preliminary human
Human trials ~8 ~3
Half-life Topical; not systemically absorbed in meaningful quantity Topical
Reported range 5-10 mg 2-5 mg
Frequency Applied topically 1-2x daily at 5-10% concentration Applied topically 1-2x daily at 2-5% concentration
Routes Topical Topical
FDA approved No No
Research use only No No
Banned in sport No No
Studied for Expression line reduction, Anti-ageing skincare Expression line reduction, Anti-ageing skincare
Reported side effects Mild local irritation, Transient redness Mild local irritation

Argireline

Argireline is a synthetic peptide patterned on the N-terminal sequence of SNAP-25, a component of the SNARE complex that mediates vesicle fusion during neurotransmitter release. By competing with native SNAP-25 for a position in the complex it modestly reduces acetylcholine release at the neuromuscular junction, softening expression-line formation. The comparison to botulinum toxin is a marketing frame rather than an equivalence: the effect is far weaker, and penetration through intact stratum corneum is the limiting factor.

Pentapeptide-18

Pentapeptide-18 is a leucine-enkephalin analog (Tyr-D-Ala-Gly-Phe-Leu) with D-alanine at position 2 for stability. It mimics the enkephalins by binding enkephalin receptors on the nerve cell, which is proposed to reduce neuronal excitability and calcium influx and so decrease acetylcholine release, moderating muscle contraction. Because it acts on a neuronal receptor while Argireline interferes with SNARE complex assembly, the two are frequently formulated together for an additive effect.

Argireline vs Pentapeptide-18: common questions

What is the difference between Argireline and Pentapeptide-18?

Both are cosmetic & topical. Argireline: A hexapeptide marketed as topical botulinum toxin, working on the same SNARE machinery by a much weaker mechanism. Pentapeptide-18: An enkephalin-derived peptide that reduces muscle contraction through a different pathway than Argireline, and is usually combined with it.

Which has stronger evidence, Argireline or Pentapeptide-18?

Argireline has the stronger evidence base (clinical trials, about 8 human studies) compared with Pentapeptide-18 (preliminary human).

Are Argireline and Pentapeptide-18 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 71587772) ↗ · structure, identifiers, synonyms
  2. CAS Registry Number 616204-22-9 ↗ · chemical identity
  3. PubChem compound record (CID 10099522) ↗ · structure, identifiers, synonyms
  4. CAS Registry Number 64963-01-5 ↗ · chemical identity

Published literature

  1. Chan LKW, Lee KWA, Lee CH, et al.. Cosmeceuticals in photoaging: A review.Skin Res Technol 2024.PubMed 39233460 · doi:10.1111/srt.13730
  2. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy.Int J Mol Sci 2025.PubMed 40565185 · doi:10.3390/ijms26125722
  3. Nagendran ST, Ali MJ, Dogru M, et al.. Complications and adverse effects of periocular aesthetic treatments.Surv Ophthalmol 2022.PubMed 33933438 · doi:10.1016/j.survophthal.2021.04.009
  4. Wisniewski JD, Ellis DL, Lupo MP. Facial rejuvenation: combining cosmeceuticals with cosmetic procedures.Cutis 2014.PubMed 25279473
  5. Bruschi M, Alberici F, Moroni G, et al.. The landscape of serum autoantibodies in lupus nephritis.Autoimmun Rev 2026.PubMed 42409299 · doi:10.1016/j.autrev.2026.104128
  6. Wang Y, Wang M, Xiao S, et al.. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.Am J Clin Dermatol 2013.PubMed 23417317 · doi:10.1007/s40257-013-0009-9
  7. Bongard O, Weimer D, Lemoine R, et al.. Cyclosporine toxicity in renal transplant recipients detected by nailfold capillaroscopy with Na-fluorescein.Kidney Int 2000.PubMed 11115091 · doi:10.1046/j.1523-1755.2000.00441.x
  8. Young B, Zhao X, Cook AR, et al.. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis.Vaccine 2017.PubMed 27939013 · doi:10.1016/j.vaccine.2016.11.013
  9. Akhan D, Bicak B, Akalin E, et al.. Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis.Comput Biol Chem 2026.PubMed 41722287 · doi:10.1016/j.compbiolchem.2026.108952
  10. Park J, Jung H, Jang B, et al.. D-tyrosine adds an anti-melanogenic effect to cosmetic peptides.Sci Rep 2020.PubMed 31937863 · doi:10.1038/s41598-019-57159-3
  11. Pawłowska M, Marzec M, Jankowiak W, et al.. Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18-Optimization, Characterization, and Cosmetic Application.Int J Mol Sci 2024.PubMed 39337562 · doi:10.3390/ijms251810078
  12. Szabó D, Schlosser G, Vékey K, et al.. Collision energies on QTof and Orbitrap instruments: How to make proteomics measurements comparable?.J Mass Spectrom 2021.PubMed 33277714 · doi:10.1002/jms.4693
  13. Akhan D, Bicak B, Kurtur OB, et al.. Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications.Chem Biodivers 2026.PubMed 42116636 · doi:10.1002/cbdv.202502546
  14. Broderick PA, Blaha CD, Lane RF. In vivo electrochemical evidence for an enkephalinergic modulation underlying stereotyped behavior: reversibility by naloxone.Brain Res 1983.PubMed 6683987 · doi:10.1016/0006-8993(83)90151-8
  15. Akhan D, Bicak B, Akman G, et al.. In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides.Cell Biochem Biophys 2026.PubMed 42412310 · doi:10.1007/s12013-026-02095-z
  16. Kuis W, Villiger PM, Leser HG, et al.. Differential processing of proenkephalin-A by human peripheral blood monocytes and T lymphocytes.J Clin Invest 1991.PubMed 1885771 · doi:10.1172/JCI115382

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.